COMPLEXES OF SIROLIMUS AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; pol |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | KÁRPÁTI, RICHARD BALÁZS ÖTVÖS, ZSOLT FENYVESI, ZSÓFIA HELTOVICS, GÁBOR FILIPCSEI, GENOVÉVA ANGI, ERZSÉBET RÉKA SOLYMOSI, TAMÁS MOLNÁR, LÁSZLÓ GLAVINAS, HRISTOS FERENCZI, KATALIN |
description | The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dubé Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PL3104844TT3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PL3104844TT3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PL3104844TT33</originalsourceid><addsrcrecordid>eNqNjb8KwjAQxrs4iPoO566gtINrSK_2IE1C7lrcSpE4iRZ099VNwAdw-vjx_VsWH-06b_CCDK4BpuAMdT2DsjWQMNQYaFBCA_IOfHAamaFxAaTFxOhVSK6zmQOmiVz0rQqd0tgLaWUgXzimHOMEVhRZsudc6dbF4jbdX3Hz01WxbVB0u4_zc4yvebrGR3yP3pTHQ3WqKpGy_CfzBXt4PM8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPLEXES OF SIROLIMUS AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM</title><source>esp@cenet</source><creator>KÁRPÁTI, RICHARD BALÁZS ; ÖTVÖS, ZSOLT ; FENYVESI, ZSÓFIA ; HELTOVICS, GÁBOR ; FILIPCSEI, GENOVÉVA ; ANGI, ERZSÉBET RÉKA ; SOLYMOSI, TAMÁS ; MOLNÁR, LÁSZLÓ ; GLAVINAS, HRISTOS ; FERENCZI, KATALIN</creator><creatorcontrib>KÁRPÁTI, RICHARD BALÁZS ; ÖTVÖS, ZSOLT ; FENYVESI, ZSÓFIA ; HELTOVICS, GÁBOR ; FILIPCSEI, GENOVÉVA ; ANGI, ERZSÉBET RÉKA ; SOLYMOSI, TAMÁS ; MOLNÁR, LÁSZLÓ ; GLAVINAS, HRISTOS ; FERENCZI, KATALIN</creatorcontrib><description>The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dubé Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose.</description><language>eng ; pol</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201019&DB=EPODOC&CC=PL&NR=3104844T3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201019&DB=EPODOC&CC=PL&NR=3104844T3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KÁRPÁTI, RICHARD BALÁZS</creatorcontrib><creatorcontrib>ÖTVÖS, ZSOLT</creatorcontrib><creatorcontrib>FENYVESI, ZSÓFIA</creatorcontrib><creatorcontrib>HELTOVICS, GÁBOR</creatorcontrib><creatorcontrib>FILIPCSEI, GENOVÉVA</creatorcontrib><creatorcontrib>ANGI, ERZSÉBET RÉKA</creatorcontrib><creatorcontrib>SOLYMOSI, TAMÁS</creatorcontrib><creatorcontrib>MOLNÁR, LÁSZLÓ</creatorcontrib><creatorcontrib>GLAVINAS, HRISTOS</creatorcontrib><creatorcontrib>FERENCZI, KATALIN</creatorcontrib><title>COMPLEXES OF SIROLIMUS AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM</title><description>The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dubé Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjb8KwjAQxrs4iPoO566gtINrSK_2IE1C7lrcSpE4iRZ099VNwAdw-vjx_VsWH-06b_CCDK4BpuAMdT2DsjWQMNQYaFBCA_IOfHAamaFxAaTFxOhVSK6zmQOmiVz0rQqd0tgLaWUgXzimHOMEVhRZsudc6dbF4jbdX3Hz01WxbVB0u4_zc4yvebrGR3yP3pTHQ3WqKpGy_CfzBXt4PM8</recordid><startdate>20201019</startdate><enddate>20201019</enddate><creator>KÁRPÁTI, RICHARD BALÁZS</creator><creator>ÖTVÖS, ZSOLT</creator><creator>FENYVESI, ZSÓFIA</creator><creator>HELTOVICS, GÁBOR</creator><creator>FILIPCSEI, GENOVÉVA</creator><creator>ANGI, ERZSÉBET RÉKA</creator><creator>SOLYMOSI, TAMÁS</creator><creator>MOLNÁR, LÁSZLÓ</creator><creator>GLAVINAS, HRISTOS</creator><creator>FERENCZI, KATALIN</creator><scope>EVB</scope></search><sort><creationdate>20201019</creationdate><title>COMPLEXES OF SIROLIMUS AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM</title><author>KÁRPÁTI, RICHARD BALÁZS ; ÖTVÖS, ZSOLT ; FENYVESI, ZSÓFIA ; HELTOVICS, GÁBOR ; FILIPCSEI, GENOVÉVA ; ANGI, ERZSÉBET RÉKA ; SOLYMOSI, TAMÁS ; MOLNÁR, LÁSZLÓ ; GLAVINAS, HRISTOS ; FERENCZI, KATALIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PL3104844TT33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; pol</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>KÁRPÁTI, RICHARD BALÁZS</creatorcontrib><creatorcontrib>ÖTVÖS, ZSOLT</creatorcontrib><creatorcontrib>FENYVESI, ZSÓFIA</creatorcontrib><creatorcontrib>HELTOVICS, GÁBOR</creatorcontrib><creatorcontrib>FILIPCSEI, GENOVÉVA</creatorcontrib><creatorcontrib>ANGI, ERZSÉBET RÉKA</creatorcontrib><creatorcontrib>SOLYMOSI, TAMÁS</creatorcontrib><creatorcontrib>MOLNÁR, LÁSZLÓ</creatorcontrib><creatorcontrib>GLAVINAS, HRISTOS</creatorcontrib><creatorcontrib>FERENCZI, KATALIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KÁRPÁTI, RICHARD BALÁZS</au><au>ÖTVÖS, ZSOLT</au><au>FENYVESI, ZSÓFIA</au><au>HELTOVICS, GÁBOR</au><au>FILIPCSEI, GENOVÉVA</au><au>ANGI, ERZSÉBET RÉKA</au><au>SOLYMOSI, TAMÁS</au><au>MOLNÁR, LÁSZLÓ</au><au>GLAVINAS, HRISTOS</au><au>FERENCZI, KATALIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPLEXES OF SIROLIMUS AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM</title><date>2020-10-19</date><risdate>2020</risdate><abstract>The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dubé Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; pol |
recordid | cdi_epo_espacenet_PL3104844TT3 |
source | esp@cenet |
subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
title | COMPLEXES OF SIROLIMUS AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T11%3A32%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=K%C3%81RP%C3%81TI,%20RICHARD%20BAL%C3%81ZS&rft.date=2020-10-19&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPL3104844TT3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |